- Home
- PMVP vs FORA Comparison
PMVP vs FORA Comparison
Compare PMVP & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | FORA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 69.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMVP | FORA |
|---|---|---|
| Price | $1.25 | $2.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 291.0K | 29.3K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,106,911.00 |
| Revenue This Year | N/A | $47.82 |
| Revenue Next Year | N/A | $10.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $0.81 | $1.64 |
| 52 Week High | $1.84 | $4.03 |
Technical Indicators
Market Signals| Indicator | PMVP | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 40.15 |
| Support Level | $1.11 | $2.11 |
| Resistance Level | $1.30 | $2.18 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 67.50 | 0.00 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.